PLK3 335-646-pEGFP Citations (3)

Originally described in: Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.
Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, Jiang N, Alberts GF, Costa M, Lu L, Winkles JA, Dai W Cancer Res. 2008 Jun 1. 68(11):4077-85. PubMed Journal

---

Articles Citing PLK3 335-646-pEGFP

Articles
Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction. Wang H, Tian C, Fan XY, Chen LN, Lv Y, Sun J, Zhao YJ, Zhang LB, Wang J, Shi Q, Gao C, Chen C, Shao QX, Dong XP. Int J Biochem Cell Biol. 2015 May;62:24-35. doi: 10.1016/j.biocel.2015.02.011. Epub 2015 Feb 25. PubMed
Overexpression of PLK3 Mediates the Degradation of Abnormal Prion Proteins Dependent on Chaperone-Mediated Autophagy. Wang H, Tian C, Sun J, Chen LN, Lv Y, Yang XD, Xiao K, Wang J, Chen C, Shi Q, Shao QX, Dong XP. Mol Neurobiol. 2016 Jun 25. PubMed
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies. Babagana M, Kichina JV, Slabodkin H, Johnson S, Maslov A, Brown L, Attwood K, Nikiforov MA, Kandel ES. Mol Carcinog. 2020 Jan;59(1):5-14. doi: 10.1002/mc.23123. Epub 2019 Sep 30. PubMed

If you have published an article using this material, please email us at to have your article added to this page.